Altered bone material properties in HLA-B27 rats include reduced mineral to matrix ratio and altered collagen cross-links.

J Bone Miner Res

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria.

Published: November 2014

Spondyloarthropathy and inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are often associated with severe osteopenia/osteoporosis in both children and adults. HLA-B27 transgenic rats present a phenotype that includes severe colitis and severely accelerated alveolar bone loss. The purpose of this study was to evaluate long bone density status, systemic bone metabolic markers, and intrinsic bone material properties in HLA-B27 transgenic (TG) rats, and compare them with those of age- and sex-matched wild-type (WT) animals. The results indicate that in the HLA-B27 rat, an animal susceptible to both alveolar bone loss (ABL) and long bone osteopenia, there is a statistically significant negative correlation between ABL and long bone bone mineral density (BMD), as well as mineral/matrix ratio at active bone-forming trabecular surfaces. The TG animals had a lower mineral/matrix ratio and higher relative proteoglycan and advanced glycation end product (ϵ-N-Carboxymethyl-L-lysine) content and pyridinoline/divalent collagen cross-link ratio compared with WT. These results may provide better understanding of the interrelationship between osteoporosis and oral bone loss, the underlying causes of the inferior bone strength in the HLA-B27 transgenic animals, and could prove to be a useful model in the elucidation of the pathophysiology of spondyloarthropathy and IBD-associated osteopenia/osteoporosis and in the evaluation of pharmacological intervention(s) against such conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.2268DOI Listing

Publication Analysis

Top Keywords

hla-b27 transgenic
12
bone loss
12
long bone
12
bone
10
bone material
8
material properties
8
properties hla-b27
8
transgenic rats
8
alveolar bone
8
abl long
8

Similar Publications

Introduction: Inflammatory bowel diseases (IBDs) are chronic immune driven intestinal disorders with marked metabolic alteration. Mass spectrometry imaging (MSI) enables the direct visualization of biomolecules within tissues and facilitates the study of metabolic changes. Integrating multiple spatial information sources is a promising approach for discovering new biomarkers and understanding biochemical alteration within the context of the disease.

View Article and Find Full Text PDF

serovar Typhimurium (STm) causes gastroenteritis and can progress to reactive arthritis (ReA). STm forms biofilms in the gut that secrete the amyloid curli, which we previously demonstrated can trigger autoimmunity in mice. HLA-B27 is a genetic risk factor for ReA; activation of the unfolded protein response (UPR) due to HLA-B27 misfolding is thought to play a critical role in ReA pathogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • HLA-B27's association with spondyloarthritis (SpA) has been studied for 50 years, revealing its impact on the bone morphogenetic protein (BMP) pathway in Drosophila, which leads to a specific phenotype.
  • Researchers investigated the genetic interactions between the TGFβ pathway and HLA-B27 in transgenic Drosophila and identified key interactions in T cells from HLA-B27/hβ2m rats.
  • The study found that both the TGFβ and BMP pathways are deregulated in the context of HLA-B27, leading to increased phosphorylation of SMAD proteins and changes in gene expression related to immune responses.
View Article and Find Full Text PDF
Article Synopsis
  • HLA-B27, a significant risk factor for spondyloarthritis (SpA), may involve impaired protein folding and subsequent inflammation pathways, particularly IL-23 induced by endoplasmic reticulum (ER) stress.
  • Researchers studied the effect of deleting the CHOP transcription factor, which influences ER stress-related IL-23 production, on gut inflammation in genetically modified rats (HLA-B27-Tg).
  • Findings revealed that removing CHOP did not reduce gut inflammation; instead, it increased other pro-inflammatory markers, suggesting that CHOP might actually help mitigate severe gut inflammation linked to HLA-B27.
View Article and Find Full Text PDF

The therapeutic management of Crohn's disease (CD), a chronic relapsing-remitting inflammatory bowel disease (IBD), is highly challenging. Surgical resection is sometimes a necessary procedure even though it is often associated with postoperative recurrences (PORs). Tofacitinib, an orally active small molecule Janus kinase inhibitor, is an anti-inflammatory drug meant to limit PORs in CD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!